Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | PARP1 | P09874 | 7/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585656 | 0.81 | IRAK1 (0.43) | KDM4EPARP1IKBKBNNMTIRAK4 | |
| SCHEMBL11973582 | 0.78 | PARP1 (0.36) | KDM4EPARP1IKBKBNNMTALDH1A1 | |
| SCHEMBL3578539 | 0.78 | IKBKB (0.38) | KDM4EPARP1IKBKBIRAK4ALDH1A1 | |
| SCHEMBL3345725 | 0.77 | KDM4E (0.47) | KDM4EPARP1IKBKBNNMTALDH1A1 | |
| SCHEMBL31443745 | 0.73 | IKBKB (0.67) | KDM4EPARP1IKBKBNNMTIRAK4 | |
| SCHEMBL22388 | 0.73 | IKBKB (0.67) | KDM4EPARP1IKBKBNNMTIRAK4 | |
| SCHEMBL3583877 | 0.72 | DGAT1 (0.36) | KDM4EPARP1IKBKBALDH1A1SMN1; SMN2 | |
| SCHEMBL13835817 | 0.72 | IKBKB (0.37) | PARP1IKBKBALDH1A1GAAKMT2A | |
| SCHEMBL28628579 | 0.71 | SMN1; SMN2 (0.62) | KDM4EPARP1IKBKBNNMTRCE1 | |
| SCHEMBL19329369 | 0.70 | PIM1 (0.49) | KDM4EPARP1NNMTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081650-A1 | Antimicrobial Compounds | AXTEN JEFFREY MICHAEL | 2010-04-01 | — | — | US | claimed |
| EP-1537123-B1 | AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | GLAXO GROUP LTD (GB) | 2009-04-29 | — | — | EP | claimed |
| EP-1799676-A2 | NEW BICYCLIC ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-27 | — | — | EP | claimed |
| US-20060189604-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | claimed |
| WO-2006032466-A2 | NEW BICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-30 | — | — | WO | claimed |
| EP-1537123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-06-08 | — | — | EP | claimed |
| WO-2004002992-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-01-08 | — | — | WO | claimed |
| US-10457662-B2 | Substituted amides for treating and preventing cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180282296-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-10-04 | — | — | US | disclosed |
| WO-2016187544-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-24 | — | — | WO | disclosed |
| US-20100081650-A1 | Antimicrobial Compounds | AXTEN JEFFREY MICHAEL | 2010-04-01 | — | — | US | disclosed |
| US-7622481-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1537123-B1 | AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | GLAXO GROUP LTD (GB) | 2009-04-29 | — | — | EP | disclosed |
| EP-2017265-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | Abbott Laboratories (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-1799676-A2 | NEW BICYCLIC ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-27 | — | — | EP | disclosed |
| US-20060189604-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
| WO-2006032466-A2 | NEW BICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-30 | — | — | WO | disclosed |
| EP-1537123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004002992-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282296-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER | NNT, NQO1, NAMPT | KDM4E 2863/4885PARP1 70/4885IKBKB 2714/4885 |
| US-10457662-B2 | Substituted amides for treating and preventing cancer | NQO1, NNT, SIRT1 | KDM4E 1342/4885PARP1 138/4885IKBKB 1633/4885 |
| US-20060189604-A1 | Compounds | ELANE, PIGS, SDHA | KDM4E 3723/4885PARP1 1578/4885IKBKB 526/4885 |
| US-20100081650-A1 | Antimicrobial Compounds | ELANE, NISCH, PIGS | KDM4E 4273/4885PARP1 2664/4885IKBKB 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.